GlobeNewswire Inc.T3·4mo ago
SCLX Scilex Holding Company
XNAS
29.08
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SCLX
$29.08
—
What changed
Recent filings, trades and movesKey stats
$29.08
- 52-Week Range
- $1.61 – $27.00
- YTD
- +122.15%
- Straddle Price
- $2.65
- P/C Vol Ratio (Sep 19 expiry)
- 0.00
- Market Cap
- $0.0B
- Open
- $1.69
- Day Range
- $1.64 – $1.77
- Volume
- 27,910
- Prev Close
- $1.70
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.21 |
| Cost of Equity (CAPM) | 10.63% (VRP-adj) |
| WACC | 7.70% |
| Volatility Risk Premium | -81.4pp (IV − HV30), ERP adj -25bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -4.2% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | 145.4% |
| Book / Price | -1770.6% |
| Gross Margin (TTM) | 65.0% |
| FCF Margin (TTM) | -58.9% |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $3.78 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $2.30 |
| Bollinger Width / SMA20 | 71.3% (drives anchor stability) |
| Net Debt | $0.0B |
| Market Cap | $0B |
Blended Fair Value
$3.78
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | n/a | 0% | |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $3.78 | 100% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 34
- List Date
- 2022-11-11
- CIK
- 0001820190
- Next Earnings
- 2026-11-13 (Pre-Market)
- Headquarters
- Palo Alto, CA
- Homepage
- https://www.scilexholding.com
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | -- | 48.49% | -19.61% | -5.61% | -34.91% | -2.91% |
| Feb | -- | 23.57% | 40.99% | -44.23% | -10.18% | 2.54% |
| Mar | -- | -3.30% | 19.10% | -14.72% | -17.68% | -4.15% |
| Apr | -- | -11.17% | -45.66% | -42.98% | 52.24% | -11.89% |
| May | -- | -1.00% | 26.23% | 0.39% | -15.88% | 2.44% |
| Jun | -- | -5.59% | 77.06% | 19.96% | -2.38% | 22.26% |
| Jul | -- | -3.87% | -15.43% | 122.19% | -14.55% | 22.09% |
| Aug | -- | -45.02% | -23.33% | 32.44% | -16.23% | -13.04% |
| Sep | -- | -54.84% | -15.95% | 5.58% | -17.59% | -20.70% |
| Oct | -- | 40.60% | 8.02% | -20.21% | -58.05% | -7.41% |
| Nov | -51.86% | -30.94% | -33.75% | 14.00% | -6.95%* | -21.90% |
| Dec | -0.75% | 51.11% | -33.50% | -37.31% | -- | -5.11% |
| Total | -52.22% | -48.41% | -57.48% | -45.39% | -86.15% | -57.93% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.25
SMA 50: $3.71
SMA 200: $6.59
Current: $1.74
EMA 12: $1.99
EMA 26: $2.58
MACD: -0.5844 | Signal: 0.0429
BEARISH
ADX (14): 46.09
STRONG TREND
+DI: 8.81
−DI: 36.45
Momentum Oscillators
RSI (14): 15.91
OVERSOLD
Stoch %K: 9.59
Stoch %D: 6.42
Williams %R: -87.13
Volume & Volatility
BB Upper: $3.07
BB Lower: $1.43
NEUTRAL
OBV: 1,930,018
Vol SMA 20: 38,223
Vol ROC: -51.29%
ATR: $0.22
True Range: $0.13
HV 20: 71.1%
HV 30: 81.7%
HV 60: 71.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-11T00:00:00 – 2026-11-09T00:00:00
AI Analysis
LLM Stock Analysis Report: SCLX
Executive Summary
BULLISH (Confidence Level: 7/10)
Key drivers: Recent positive news, Datavault AI investment, and moderate volatility.
Primary risks: Potential for a pullback if the stock fails to break above the upper Bollinger Band, and market fluctuations.
Investment thesis: SCLX has the potential to continue its upward trend, driven by recent news and moderate volatility.
Recent news sentiment impact: Positive news headlines have contributed to the stock's upward momentum.
Technical Analysis
Trend Direction: Short-term: Uptrend, Medium-term: Neutral, Long-term: Uptrend
Support/Resistance Levels: Upper Bollinger Band ($21.83), Middle SMA 50 ($19.17), Lower SMA 200 ($12.39)
Momentum Signals:
- RSI (14): 55.31 (neutral)
- MACD: Bullish signal
- Bollinger Bands: Neutral signal
Volume Analysis: Volume SMA 20: 155872.05, On-Balance Volume (OBV): 2275977.66, Volume Rate of Change: -9.31%
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines from Datavault AI investment and Scilex Holding Company's equity financing.
Sentiment Assessment: Positive sentiment with a score of 0.8/1 (Very Bullish).
Catalyst Identification: Upcoming earnings announcement on 2025-06-23, potential product launches in the healthcare sector.
Market Narrative: The recent news has contributed to the stock's upward momentum, aligning with the technical signals.
Risk & Volatility Assessment
Beta Interpretation: Beta: 0.95 (vs SPY), moderate volatility - stock generally follows market.
Volatility Regime: Current vs historical volatility levels: Low (1.31).
Options Market Signals: IV Rank: 0.0% (Low), Put/Call Volume Ratio: 0.00 (Bullish sentiment), Market Expectation: Options market pricing $2.65 move by expiration.
Downside Protection: Support levels at SMA 50 ($19.17) and SMA 200 ($12.39).
Market Context & Positioning
Sector Performance: Relative strength vs sector/market: Healthcare ( Bullish)
Institutional Activity: Volume patterns suggesting institutional interest: 1,627 calls vs 30 puts.
Correlation Analysis: R-squared interpretation: SCLX has a moderate correlation with the market.
Relative Valuation: Position within trading range: Neutral
Key Levels & Action Items
Critical Price Levels: Support at SMA 50 ($19.17) and SMA 200 ($12.39), Resistance at Upper Bollinger Band ($21.83).
Breakout/Breakdown Levels: Break above Upper Bollinger Band for a potential further upside, break below SMA 200 for a potential pullback.
Time-Sensitive Catalysts: Earnings announcement on 2025-06-23 and potential product launches in the healthcare sector.
Risk Management: Stop-loss levels at SMA 50 ($19.17) and SMA 200 ($12.39), position sizing considerations based on market volatility.
This comprehensive analysis provides an overview of SCLX's technical, fundamental, and sentiment aspects, highlighting both bullish and bearish cases. The report concludes that the stock has a moderate level of risk, with potential for further upside driven by recent news and moderate volatility.
Generated
News
All SCLX news →
BenzingaT3·4mo ago
BenzingaT3·5mo ago
BenzingaT3·5mo ago
GlobeNewswire Inc.T3·6mo ago
BenzingaT3·6mo ago
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·9mo ago
BenzingaT3·10mo ago
GlobeNewswire Inc.T3·10mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
6 of 6 under expected move
Avg Expected Move
80.62%
Avg Actual Move
6.25%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-05-03 | Pre-Market | 49.69% | 12.94% | 0.26x | Within |
| 2023-09-11 | Pre-Market | 15.89% | 5.12% | 0.32x | Within |
| 2023-11-01 | Pre-Market | 46.81% | 3.21% | 0.07x | Within |
| 2024-03-05 | Pre-Market | 24.83% | 2.24% | 0.09x | Within |
| 2024-08-01 | Pre-Market | 322.33% | 5.66% | 0.02x | Within |
| 2024-10-08 | Pre-Market | 24.19% | 8.34% | 0.34x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
SCLX Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $2.65
7-DTE Move: $2.65
Days to Exp: — (2025-09-19)
Options Flow · Sep 19 expiry
Call Volume: 397
Put Volume: 1
P/C Volume: 0.003
BULLISH
Call OI: 1,627
Put OI: 30
P/C OI: 0.018
Total OI: 1,657
ATM Options Pricing
ATM Call: $0.03
ATM Put: $2.62
Call %: 0.1%
Put %: 9.0%
Chain Summary
Chain Volume: 398
Chain OI: 1,657
Last Updated: 9/19/2025
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Sep 15 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Sep 15 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$2.65Sep 19
Beta Analysis
Risk Metrics
Beta: 1.0318
Alpha: -202.47%
Correlation: 0.1428
R-Squared: 2.0%
Stock Volatility: 99.4%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own SCLX
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $258K | #2822 of 3138 | -10.3% | 13F | |
| Citadel Hedge fund Ken Griffin | $214K | #5422 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SCLX Institutional Ownership (13F)
Filings for 2026-06-30 · 29 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 11,449,500 (as of 2025-12-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
SCLX Insider Trading (Form 4)
Latest: 2026-07-07Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-07 | SCLX Stock Acquisition JV LLC | 10%+ Owner | Other (J) | −500,000 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SCLX Insider Holdings
1 insider · @ $1.74
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | SCLX Stock Acquisition JV LLC | 10%+ Owner | 958,263 | $1.67M | $0 | 1 | 2026-07-07 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SCLX Board & Officers
As of SEC filings through Jul 7, 2026Directors 3
- Jay Chun · since Sep 22, 2023
- Yue Alexander Wu · since Sep 22, 2023
- Stephen Hoi Ma · listed since Oct 2025
Officers 2
- Stephen Hoi Ma · Chief Financial Officer · since Sep 22, 2023
- Henry Ji · Executive Chairperson · since Nov 10, 2022
10% owners 2
- SCLX Stock Acquisition JV LLC (entity) · since Sep 22, 2023
- Scilex Holding Co (entity) · on file since Dec 2025
Changes in the last 10 years (50)
| Dec 30, 2025 | Scilex Holding Co first on file as a 10% owner |
| Oct 9, 2025 | Stephen Hoi Ma first listed as a director in an SEC filing |
| Sep 22, 2025 | The company announced the departure of Annu Navani from the board in an SEC filing |
| Aug 16, 2025 | The company announced the departure of Jaisim Shah as Chief Executive Officer and President in an SEC filing |
| Jul 21, 2024 | Annu Navani became a director |
| Sep 25, 2023 | Sorrento Therapeutics, Inc. reported in an SEC filing no longer being a 10% owner |
| Sep 22, 2023 | Yue Alexander Wu became a director |
| Sep 22, 2023 | Stephen Hoi Ma became Chief Financial Officer |
| Sep 22, 2023 | SCLX Stock Acquisition JV LLC became a 10% owner |
| Sep 22, 2023 | Jay Chun became a director |
| Sep 20, 2023 | The company announced the departure of Elizabeth Czerepak as Executive Vice President, Chief Business Officer and Chief Financial Officer in an SEC filing |
| Aug 29, 2023 | The company announced the departure of Jaisim Shah from the board in an SEC filing |
| Aug 28, 2023 | The company announced the departure of Dorman Followwill from the board in an SEC filing |
| Aug 28, 2023 | The company announced the departure of David Lemus from the board in an SEC filing |
| Aug 27, 2023 | The company announced the departure of Tien-Li Lee from the board in an SEC filing |
| Aug 27, 2023 | The company announced the departure of Laura Hamill from the board in an SEC filing |
| Aug 27, 2023 | The company announced the departure of Henry Ji from the board in an SEC filing |
| Nov 15, 2022 | Vickers Venture Fund VI Pte Ltd reported in an SEC filing no longer being a 10% owner |
| Nov 15, 2022 | Vickers Venture Fund VI (Plan) Pte Ltd reported in an SEC filing no longer being a 10% owner |
| Nov 15, 2022 | Jeffrey Chi reported in an SEC filing no longer being an officer |
| Nov 15, 2022 | Jeffrey Chi reported in an SEC filing no longer being a director |
| Nov 15, 2022 | Jeffrey Chi reported in an SEC filing no longer being a 10% owner |
| Nov 15, 2022 | Chris Ho reported in an SEC filing no longer being an officer |
| Nov 15, 2022 | Chris Ho reported in an SEC filing no longer being a director |
| Nov 15, 2022 | Chris Ho reported in an SEC filing no longer being a 10% owner |
| Nov 10, 2022 | Tommy G Thompson became a director |
| Nov 10, 2022 | Tien-Li Lee became a director |
| Nov 10, 2022 | Suneel G Kaji left the board, per their own SEC filing |
| Nov 10, 2022 | Steve Myint left the board, per their own SEC filing |
| Nov 10, 2022 | Sorrento Therapeutics, Inc. became a 10% owner |
| Nov 10, 2022 | Pei Wei Woo left the board, per their own SEC filing |
| Nov 10, 2022 | Laura Hamill became a director |
| Nov 10, 2022 | Jaisim Shah became a director |
| Nov 10, 2022 | Jaisim Shah became Chief Executive Officer and President |
| Nov 10, 2022 | Henry Ji became a director |
| Nov 10, 2022 | Henry Ji became Executive Chairperson |
| Nov 10, 2022 | Elizabeth Czerepak became Executive Vice President, Chief Business Officer and Chief Financial Officer |
| Nov 10, 2022 | Dorman Followwill became a director |
| Nov 10, 2022 | David Lemus became a director |
| Jan 6, 2021 | Vickers Venture Fund VI Pte Ltd became a 10% owner |
| Jan 6, 2021 | Vickers Venture Fund VI (Plan) Pte Ltd became a 10% owner |
| Jan 6, 2021 | Suneel G Kaji became a director |
| Jan 6, 2021 | Steve Myint became a director |
| Jan 6, 2021 | Pei Wei Woo became a director |
| Jan 6, 2021 | Jeffrey Chi became an officer |
| Jan 6, 2021 | Jeffrey Chi became a director |
| Jan 6, 2021 | Jeffrey Chi became a 10% owner |
| Jan 6, 2021 | Chris Ho became an officer |
| Jan 6, 2021 | Chris Ho became a director |
| Jan 6, 2021 | Chris Ho became a 10% owner |
Not reported recently (1)
- Tommy G Thompson · Last reported as a director in an SEC filing dated Jan 17, 2023
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-09-29
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-09-29 | Material agreement | EDGAR |
| 2026-08-12 | Material agreement | EDGAR |
| 2026-07-22 | Material agreement · Acquisition or sale completed | EDGAR |
| 2026-07-06 | Material agreement · Unregistered share sale · Regulation FD disclosure | EDGAR |
| 2026-06-29 | Material agreement · Unregistered share sale | EDGAR |
| 2026-06-24 | Shareholder vote results | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-14 | 0001193125-26-352464 | EDGAR |
ETF Holders
4 ETFs hold SCLX
4 shown · $1.35M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $967,920 | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $339,224 | — | 2026-09-30 |
| 3 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.00% | $40,690 | $1.2B | 2026-11-06 |
| 4 | AVTM Avantis Total Equity Markets ETF | Avantis | 0.00% | $136 | $742.8M | 2026-11-05 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-36.45
TTM Revenue
$30.25M
TTM Net Income
$-402.49M
TTM Op. Cash Flow
$3.82M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q4 '25 | 2025-12-31 | $4.79M | $-33.11M | $-4.60 | $-17.47M |
| Q3 '25 | 2025-09-30 | $10.56M | $-257.23M | $-22.17 | $8.23M |
| Q2 '25 | 2025-06-30 | $9.90M | $-86.06M | $-7.42 | $7.05M |
| Q1 '25 | 2025-03-31 | $5.00M | $-26.08M | $-2.26 | $6.01M |
| Q4 '24 | 2024-12-31 | $14.90M | $-6.46M | $4.72 | $2.53M |
| Q3 '24 | 2024-09-30 | $14.44M | $-4.39M | $-0.58 | $5.11M |
| Q2 '24 | 2024-06-30 | $16.37M | $-37.58M | $-7.67 | $2.31M |
| Q1 '24 | 2024-03-31 | $10.88M | $-24.38M | $-8.33 | $9.39M |
| Q4 '23 | 2023-12-31 | $13.46M | $-21.40M | $-8.75 | $-5.39M |
| Q3 '23 | 2023-09-30 | $10.12M | $-88.17M | $-22.05 | $5.90M |
| Q2 '23 | 2023-06-30 | $12.58M | $-26.65M | $-6.65 | $-13.47M |
| Q1 '23 | 2023-03-31 | $10.58M | $-30.75M | $-7.70 | $-7.74M |
Q4 2025 • period ending 2025-12-31 • filed 2026-04-10
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
0.66
EV/EBITDA
—
EV/Sales
1.24
ROE
—
ROA
-110.3%
Div Yield
0.00%
FCF Yield
19.15%
Debt/Equity
—
Current Ratio
—
Market Cap
$19.92M
as of 2026-11-09
SCLX vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| AMGN Amgen Inc | $249.0B | 27.0 | +8.2% | +42.0% | 32 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.2% | 47 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +771.7% | 53 |
| ARGX argenx SE American Depositary Shares | $58.3B | — | — | +14.6% | 58 |
| RVMD Revolution Medicines, Inc. Common Stock | $41.6B | — | — | +153.3% | 60 |
| BIIB Biogen Inc. Common Stock | $36.7B | 108.9 | +2.3% | +43.3% | 100 |
| BNTX BioNTech SE American Depositary Share | $21.7B | — | — | −9.5% | 45 |
| EXEL Exelixis Inc | $17.0B | 21.5 | +9.1% | +64.6% | 47 |
| SCLX Scilex Holding Company Common Stock | $12M | — | −46.5% | −86.7% | — |
| Peer median | $49.9B | 27.0 | +6.5% | +42.7% | 50 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
148.38K
SI % of Float
2.18%
Days to Cover
2.63
Short Vol Ratio
17.2%
Free Float
6.80M
Float %
80.0%
Short interest 2026-10-15 • Short volume 2026-11-09 • Float 2026-09-22